

July 25, 2024



Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

- Presentation to highlight positive outcomes of lomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemia
- lomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemia

NEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3rd Annual Targeted Radiopharmaceuticals Summit US, being held in San Diego, CA, from July 30 – August 1, 2024. Actinium's presentation titled, "Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates," will take place on Wednesday, July 31, 2024th. The presentation will highlight the following:



- Exploring lomab-B, a CD45 I-131 ARC, to enable bone marrow transplant (BMT) in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
- Outlining responses in heavily pretreated patients for both lomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutated disease, to demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
- Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response

For more information about the Targeted Radiopharmaceutical Summit and the conference agenda, please visit <https://targeted-radiopharma-us.com/>.

About Actinium Pharmaceuticals, Inc.

Actinium develops targeted radiotherapies to meaningfully improve survival for people who

have failed existing oncology therapies. Advanced pipeline candidates lomab-B (pre-BLA & MAA (EU)), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance lomab-B for other blood cancers and next generation conditioning candidate lomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: <https://www.actiniumpharma.com/>

Contact:

investorrelations@actiniumpharma.com

View original content to download multimedia: <https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-at-the-3rd-annual-targeted-radiopharmaceuticals-summit-us-302206068.html>

SOURCE Actinium Pharmaceuticals, Inc.